FURTHER EVIDENCE FOR MULTIPLE FORMS OF AN N-METHYL-D-ASPARTATE RECOGNITION DOMAIN IN RAT-BRAIN USING MEMBRANE-BINDING TECHNIQUES

被引:14
作者
ZUO, PP [1 ]
OGITA, K [1 ]
SUZUKI, T [1 ]
HAN, D [1 ]
YONEDA, Y [1 ]
机构
[1] SETSUNAN UNIV,FAC PHARMACEUT SCI,DEPT PHARMACOL,45-1 NAGAOTOGE CHO,HIRAKATA,OSAKA 57301,JAPAN
关键词
N-METHYL-D-ASPARTATE; H-3]CGP-39653 BINDING; H-3]GLUTAMATE BINDING; ANTAGONIST-PREFERRING FORM; AGONIST-PREFERRING FORM; MULTIPLICITY;
D O I
10.1111/j.1471-4159.1993.tb09828.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Pretreatment with sulfhydryl-reactive agents, such as N-ethylmaleimide and p-chloromercuriphenylsulfonic acid, invariably resulted in marked inhibition of the binding Of DL-(E)-2-amino-4-[H-3]propyl-5-phosphono-3-pentenoic acid ([H-3]CGP 39653), a competitive antagonist at an N-methyl-D-aspartate (NMDA)-sensitive subclass of central excitatory amino acid receptors, in brain synaptic membranes extensively washed and treated with Triton X-1 00, but did not significantly affect the binding of L-[H-3]glutamic acid ([H-3]Glu), an endogenous agonist. The pretreatment was effective in reducing the binding of [H-3]CGP 39653 at equilibrium, without altering the initial association rate, and decreased the affinity for the ligand. Pretreatment with sulfhydryl-reactive agents also enhanced the potencies of NMDA agonists to displace [H-3]CGP 39653 binding and attenuated those of NMDA antagonists, but had little effect on the potencies of the agonists and antagonists to displace [H-3]Glu binding. The binding of both [H-3]CGP 39653 and [H-3]Glu was similarly sensitive to pretreatment with four different proteases in Triton-treated membranes, whereas pretreatment with phospholipase A, or C markedly inhibited [H-3]CGP 39653 binding without altering [H-3]Glu binding. Moreover, both phospholipases not only induced enhancement of the abilities of NMDA agonists to displace the binding of [H-3]CGP 39653 and [H-3]Glu, but also caused diminution of those of NMDA antagonists. These results suggest that both sulfhydryl-reactive agents and phospholipases may predominantly interfere with radiolabeling of the NMDA recognition domain in a state favorable to an antagonist by [H-3]CGP 39653, with concomitant facilitation of that in an agonist-preferring form by [H-3]Glu. The possible presence of multiple forms of the NMDA recognition domain is further supported by these data.
引用
收藏
页码:1865 / 1873
页数:9
相关论文
共 33 条
[1]   EVIDENCE FOR A FUNCTIONAL COUPLING OF THE NMDA AND GLYCINE RECOGNITION SITES IN SYNAPTIC PLASMA-MEMBRANES [J].
COMPTON, RP ;
HOOD, WF ;
MONAHAN, JB .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1990, 188 (01) :63-70
[2]   SELECTIVE ASSOCIATION OF N-METHYL ASPARTATE AND QUISQUALATE TYPES OF L-GLUTAMATE RECEPTOR WITH BRAIN POSTSYNAPTIC DENSITIES [J].
FAGG, GE ;
MATUS, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1984, 81 (21) :6876-6880
[3]   SPECIFIC BINDING OF [H-3]-+2-AMINO-7-PHOSPHONO HEPTANOIC ACID TO RAT-BRAIN MEMBRANES INVITRO [J].
FERKANY, JW ;
COYLE, JT .
LIFE SCIENCES, 1983, 33 (13) :1295-1305
[4]   COMPARISON OF L-[H-3]GLUTAMATE, D-[H-3]ASPARTATE, DL-[H-3]AP5 AND [H-3] NMDA AS LIGANDS FOR NMDA RECEPTORS IN CRUDE POSTSYNAPTIC DENSITIES FROM RAT-BRAIN [J].
FOSTER, AC ;
FAGG, GE .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1987, 133 (03) :291-300
[5]   MOLECULAR TARGET SIZE ANALYSES OF THE NMDA-RECEPTOR COMPLEX IN RAT CORTEX [J].
HONORE, T ;
DREJER, J ;
NIELSEN, EO ;
WATKINS, JC ;
OLVERMAN, HJ ;
NIELSEN, M .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1989, 172 (03) :239-247
[6]   ARE SULFHYDRYL-GROUPS ESSENTIAL FOR FUNCTION OF THE GLUTAMATE-OPERATED RECEPTOR IONOPHORE COMPLEX [J].
KISKIN, NI ;
KRISHTAL, OA ;
TSYNDRENKO, AY ;
AKAIKE, N .
NEUROSCIENCE LETTERS, 1986, 66 (03) :305-310
[7]   MOLECULAR DIVERSITY OF THE NMDA RECEPTOR CHANNEL [J].
KUTSUWADA, T ;
KASHIWABUCHI, N ;
MORI, H ;
SAKIMURA, K ;
KUSHIYA, E ;
ARAKI, K ;
MEGURO, H ;
MASAKI, H ;
KUMANISHI, T ;
ARAKAWA, M ;
MISHINA, M .
NATURE, 1992, 358 (6381) :36-41
[8]  
LODGE D, 1991, TRENDS PHARMACOL SCI, P1
[9]  
LOWRY OH, 1951, J BIOL CHEM, V193, P265